

Asymptomatic transmission and the resurgence of Bor

BMC Medicine

13, 146

DOI: [10.1186/s12916-015-0382-8](https://doi.org/10.1186/s12916-015-0382-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Detection of <i>Bordetella pertussis</i> using a PCR test in infants younger than one year old hospitalized with whooping cough in five Peruvian hospitals. <i>International Journal of Infectious Diseases</i> , 2015, 41, 36-41.	1.5	26
2	New Insight into Filamentous Hemagglutinin Secretion Reveals a Role for Full-Length FhaB in <i>Bordetella</i> Virulence. <i>MBio</i> , 2015, 6, .	1.8	28
3	Defining long-term drivers of pertussis resurgence, and optimal vaccine control strategies. <i>Vaccine</i> , 2015, 33, 5794-5800.	1.7	25
4	Mechanism and Function of Type IV Secretion During Infection of the Human Host. , 0, , 265-303.		0
5	Factors influencing the spread of pertussis in households: a prospective study, Catalonia and Navarre, Spain, 2012 to 2013. <i>Eurosurveillance</i> , 2016, 21, .	3.9	17
6	Emerging cases of pertussis among early infants born to unvaccinated mothers, an infectious disease long absent in Northwestern Greece. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017043.	0.5	2
7	Pertussis Toxin Exploits Host Cell Signaling Pathways Induced by Meningitis-Causing <i>E. coli</i> K1-RS218 and Enhances Adherence of Monocytic THP-1 Cells to Human Cerebral Endothelial Cells. <i>Toxins</i> , 2016, 8, 291.	1.5	3
8	Rediscovering Pertussis. <i>Frontiers in Pediatrics</i> , 2016, 4, 52.	0.9	21
9	Dismantling the Taboo against Vaccines in Pregnancy. <i>International Journal of Molecular Sciences</i> , 2016, 17, 894.	1.8	16
10	Using Combined Diagnostic Test Results to Hindcast Trends of Infection from Cross-Sectional Data. <i>PLoS Computational Biology</i> , 2016, 12, e1004901.	1.5	15
11	Concentrations of Immunoglobulin G Antibodies Against Pertussis Toxin Does Not Decrease Over a Long Period of Time in Japan. <i>Internal Medicine</i> , 2016, 55, 3257-3263.	0.3	4
12	Live pertussis vaccines: will they protect against carriage and spread of pertussis?. <i>Clinical Microbiology and Infection</i> , 2016, 22, S96-S102.	2.8	17
13	Mechanism and Function of Type IV Secretion During Infection of the Human Host. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	57
14	Epidemiological and Economic Effects of Priming With the Whole-Cell <i>Bordetella pertussis</i> Vaccine. <i>JAMA Pediatrics</i> , 2016, 170, 459.	3.3	22
15	Cost-effectiveness of next-generation vaccines: The case of pertussis. <i>Vaccine</i> , 2016, 34, 3405-3411.	1.7	3
16	Pertussis Vaccine Effectiveness in the Setting of Pertactin-Deficient Pertussis. <i>Pediatrics</i> , 2016, 137, .	1.0	53
17	Pertussis: Where did we go wrong and what can we do about it?. <i>Journal of Infection</i> , 2016, 72, S34-S40.	1.7	20
18	Investigating the pertussis resurgence in England and Wales, and options for future control. <i>BMC Medicine</i> , 2016, 14, 121.	2.3	52

#	ARTICLE	IF	CITATIONS
19	The Pertussis resurgence: putting together the pieces of the puzzle. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2016, 2, 26.	0.9	28
20	The pertussis enigma: reconciling epidemiology, immunology and evolution. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2016, 283, 20152309.	1.2	104
21	Comparison of Three Whole-Cell Pertussis Vaccines in the Baboon Model of Pertussis. <i>Vaccine Journal</i> , 2016, 23, 47-54.	3.2	45
22	<i>Bordetella pertussis</i> epidemiology and evolution in the light of pertussis resurgence. <i>Infection, Genetics and Evolution</i> , 2016, 40, 136-143.	1.0	64
23	Pertussis: acellular, whole-cell, new vaccines, what to choose?. <i>Expert Review of Vaccines</i> , 2016, 15, 671-673.	2.0	15
24	Immunity against vaccine-preventable diseases in Finnish pediatric healthcare workers in 2015. <i>Vaccine</i> , 2017, 35, 1608-1614.	1.7	19
25	Population-Based Pertussis Incidence and Risk Factors in Infants Less Than 6 Months in Nepal. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, 33-39.	0.6	6
26	Geospatial analysis of nonmedical vaccine exemptions and pertussis outbreaks in the United States. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7101-7105.	3.3	45
27	Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against <i>Bordetella pertussis</i> Disease and Infection. <i>Journal of Infectious Diseases</i> , 2017, 216, 117-124.	1.9	67
28	What Is Wrong with Pertussis Vaccine Immunity?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a029454.	2.3	82
29	The BvgAS Regulon of <i>Bordetella pertussis</i> . <i>MBio</i> , 2017, 8, .	1.8	61
30	Identifying transmission routes of <i>Streptococcus pneumoniae</i> and sources of acquisitions in high transmission communities. <i>Epidemiology and Infection</i> , 2017, 145, 2750-2758.	1.0	52
31	Pertussis disease and transmission and host responses: insights from the baboon model of pertussis. <i>Journal of Infection</i> , 2017, 74, S114-S119.	1.7	35
32	The pertussis hypothesis: <i>Bordetella pertussis</i> colonization in the pathogenesis of Alzheimer's disease. <i>Immunobiology</i> , 2017, 222, 228-240.	0.8	18
33	Parents as source of pertussis transmission in hospitalized young infants. <i>Infection</i> , 2017, 45, 171-178.	2.3	29
35	Public health measures for pertussis prevention and control. <i>Australian and New Zealand Journal of Public Health</i> , 2017, 41, 557-560.	0.8	4
36	An Extracellular Polysaccharide Locus Required for Transmission of <i>Bordetella bronchiseptica</i> . <i>Journal of Infectious Diseases</i> , 2017, 216, 899-906.	1.9	8
37	A compartmental network model for the spread of whooping cough. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
38	A New Whooping Cough Vaccine That May Prevent Colonization and Transmission. <i>Vaccines</i> , 2017, 5, 43.	2.1	4
39	Quantifying the contribution of asymptomatic infection to the cumulative incidence. <i>Epidemiology and Infection</i> , 2017, 145, 1256-1258.	1.0	4
40	Controlling pertussis: how can we do it? A focus on immunization. <i>Expert Review of Vaccines</i> , 2018, 17, 289-297.	2.0	24
41	Effectiveness of maternal pertussis vaccination in preventing infection and disease in infants: The NSW Public Health Network case-control study. <i>Vaccine</i> , 2018, 36, 1887-1892.	1.7	73
42	Primary transcriptome analysis reveals importance of IS elements for the shaping of the transcriptional landscape of <i>Bordetella pertussis</i> . <i>RNA Biology</i> , 2018, 15, 967-975.	1.5	32
43	School-age children and adolescents suspected of having been to be infected with pertussis in Japan. <i>Vaccine</i> , 2018, 36, 2910-2915.	1.7	10
44	Pertussis and the Minnesota State Fair: Demonstrating a Novel Setting for Efficiently Conducting Seroepidemiologic Studies. <i>Journal of Community Health</i> , 2018, 43, 937-943.	1.9	2
45	Core pertussis transmission groups in England and Wales: A tale of two eras. <i>Vaccine</i> , 2018, 36, 1160-1166.	1.7	8
46	<i>Bordetella pertussis</i> (Bp) disease: Before (2003-2011) and after (2013-2016) maternal immunization strategy in a pediatric hospital. <i>Vaccine</i> , 2018, 36, 1375-1380.	1.7	16
47	Construction and evaluation of <i>Bordetella pertussis</i> live attenuated vaccine strain BPZE1 producing Fim3. <i>Vaccine</i> , 2018, 36, 1345-1352.	1.7	10
48	Effectiveness of acellular pertussis vaccine and evolution of pertussis incidence in the community of Madrid from 1998 to 2015. <i>Vaccine</i> , 2018, 36, 1643-1649.	1.7	14
49	Immunization during pregnancy. <i>Expert Review of Vaccines</i> , 2018, 17, 383-393.	2.0	8
50	Fatal malignant pertussis with hyperleukocytosis in a Chinese infant. <i>Medicine (United States)</i> , 2018, 97, e0549.	0.4	8
51	The impact of past vaccination coverage and immunity on pertussis resurgence. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	76
52	Pertussis and Rotavirus Vaccines - Controversies and Solutions. <i>Indian Journal of Pediatrics</i> , 2018, 85, 53-59.	0.3	3
53	Marked Underreporting of Pertussis Requiring Hospitalization in Infants as Estimated by Capture-Recapture Methodology, Germany, 2013-2015. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 119-125.	1.1	15
54	Resurgence of Pertussis and Emergence of the Ptxp3 Toxin Promoter Allele in South Italy. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, e126-e131.	1.1	9
55	Diagnostic performance of commercial serological assays measuring <i>Bordetella pertussis</i> IgG antibodies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 157-162.	0.8	5

#	ARTICLE	IF	CITATIONS
56	Will we have new pertussis vaccines?. <i>Vaccine</i> , 2018, 36, 5460-5469.	1.7	33
57	Preventive and Protective Properties of Pertussis Vaccines: Current Situation and Future Challenges. , O, , .		0
59	Fol and Age-Dependent Incidence. <i>Use R!</i> , 2018, , 57-80.	0.3	0
60	Infection-acquired versus vaccine-acquired immunity in an SIRWS model. <i>Infectious Disease Modelling</i> , 2018, 3, 118-135.	1.2	8
61	Age-appropriate compliance and completion of up to five doses of pertussis vaccine in US children. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2932-2939.	1.4	3
62	Seasonality of respiratory viruses causing hospitalizations for acute respiratory infections in children in Nha Trang, Vietnam. <i>International Journal of Infectious Diseases</i> , 2018, 75, 18-25.	1.5	31
63	Could this be whooping cough?. <i>Emergency Medicine Journal</i> , 2018, 35, 639-642.	0.4	4
64	IL-17-dependent SIgA-mediated protection against nasal <i>Bordetella pertussis</i> infection by live attenuated BPZE1 vaccine. <i>Mucosal Immunology</i> , 2018, 11, 1753-1762.	2.7	55
65	The pertussis hypothesis: <i>Bordetella pertussis</i> colonization in the etiology of asthma and diseases of allergic sensitization. <i>Medical Hypotheses</i> , 2018, 120, 101-115.	0.8	13
66	Sustained protective immunity against <i>Bordetella pertussis</i> nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells. <i>Mucosal Immunology</i> , 2018, 11, 1763-1776.	2.7	98
67	Contributions from the silent majority dominate dengue virus transmission. <i>PLoS Pathogens</i> , 2018, 14, e1006965.	2.1	118
68	Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1213-1222.	2.9	16
69	Pertussis: New preventive strategies for an old disease. <i>Paediatric Respiratory Reviews</i> , 2019, 29, 68-73.	1.2	22
70	Seroepidemiology of pertussis in Hangzhou, China, during 2009â€“2017. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2564-2570.	1.4	4
71	Human Immune Responses to Pertussis Vaccines. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1183, 99-113.	0.8	6
72	Pertussis Vaccines and Vaccination Strategies. An Ever-Challenging Health Problem. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1183, 161-167.	0.8	0
73	A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero. <i>Vaccines</i> , 2019, 7, 147.	2.1	12
74	Intranasal acellular pertussis vaccine provides mucosal immunity and protects mice from <i>Bordetella pertussis</i> . <i>Npj Vaccines</i> , 2019, 4, 40.	2.9	33

#	ARTICLE	IF	CITATIONS
75	The Role of Mucosal Immunity in Pertussis. <i>Frontiers in Immunology</i> , 2018, 9, 3068.	2.2	47
77	Pertussis vaccines and protective immunity. <i>Current Opinion in Immunology</i> , 2019, 59, 72-78.	2.4	70
78	The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review. <i>Expert Review of Vaccines</i> , 2019, 18, 439-455.	2.0	52
79	Neonatal Immunity to <i>Bordetella pertussis</i> Infection and Current Prevention Strategies. <i>Journal of Immunology Research</i> , 2019, 2019, 1-10.	0.9	20
80	Immunization with whole cell but not acellular pertussis vaccines primes CD4 T _{RM} cells that sustain protective immunity against nasal colonization with <i>Bordetella pertussis</i> . <i>Emerging Microbes and Infections</i> , 2019, 8, 169-185.	3.0	75
81	Does the economic recession influence the incidence of pertussis in a cosmopolitan European city?. <i>BMC Public Health</i> , 2019, 19, 144.	1.2	6
82	Tracking U.S. Pertussis Incidence: Correlation of Public Health Surveillance and Google Search Data Varies by State. <i>Scientific Reports</i> , 2019, 9, 19801.	1.6	6
83	Vaccine-driven virulence evolution: consequences of unbalanced reductions in mortality and transmission and implications for pertussis vaccines. <i>Journal of the Royal Society Interface</i> , 2019, 16, 20190642.	1.5	14
84	PERISCOPE: road towards effective control of pertussis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e179-e186.	4.6	67
85	Toward a Controlled Human Infection Model of Pertussis. <i>Clinical Infectious Diseases</i> , 2020, 71, 412-414.	2.9	10
86	Controlled Human Infection With <i>Bordetella pertussis</i> Induces Asymptomatic, Immunizing Colonization. <i>Clinical Infectious Diseases</i> , 2020, 71, 403-411.	2.9	40
87	Asymptomatic Infection and Transmission of Pertussis in Households: A Systematic Review. <i>Clinical Infectious Diseases</i> , 2020, 70, 152-161.	2.9	18
89	Evolution and Conservation of <i>Bordetella</i> Intracellular Survival in Eukaryotic Host Cells. <i>Frontiers in Microbiology</i> , 2020, 11, 557819.	1.5	5
90	Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1290-1301.	4.6	34
91	Beyond R_0 : heterogeneity in secondary infections and probabilistic epidemic forecasting. <i>Journal of the Royal Society Interface</i> , 2020, 17, 20200393.	1.5	59
92	Acellular Pertussis Vaccine Inhibits <i>Bordetella pertussis</i> Clearance from the Nasal Mucosa of Mice. <i>Vaccines</i> , 2020, 8, 695.	2.1	25
93	The potential for improved protection against pertussis. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1220-1222.	4.6	1
95	Transversal sero-epidemiological study of <i>Bordetella pertussis</i> in Tehran, Iran. <i>PLoS ONE</i> , 2020, 15, e0238398.	1.1	4

#	ARTICLE	IF	CITATIONS
96	Acellular Pertussis Vaccines Induce Anti-pertactin Bactericidal Antibodies Which Drives the Emergence of Pertactin-Negative Strains. <i>Frontiers in Microbiology</i> , 2020, 11, 2108.	1.5	27
97	Next-Generation Pertussis Vaccines Based on the Induction of Protective T Cells in the Respiratory Tract. <i>Vaccines</i> , 2020, 8, 621.	2.1	27
98	Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework. <i>MBio</i> , 2020, 11, .	1.8	54
99	Tdap vaccination during pregnancy interrupts a twenty-year increase in the incidence of pertussis. <i>Vaccine</i> , 2020, 38, 2700-2706.	1.7	15
100	A qPCR assay for <i>Bordetella pertussis</i> cells that enumerates both live and dead bacteria. <i>PLoS ONE</i> , 2020, 15, e0232334.	1.1	3
101	Development and Validation of a <i>Bordetella pertussis</i> Whole-Genome Screening Strategy. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	23
102	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021, 174, 221-228.	2.0	86
103	Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial. <i>Clinical Microbiology and Infection</i> , 2021, 27, 878-885.	2.8	9
104	Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. <i>Frontiers in Immunology</i> , 2020, 11, 618685.	2.2	87
105	Suppression of mucosal Th17 memory responses by acellular pertussis vaccines enhances nasal <i>Bordetella pertussis</i> carriage. <i>Npj Vaccines</i> , 2021, 6, 6.	2.9	30
106	Intranasal Immunization with Acellular Pertussis Vaccines Results in Long-Term Immunity to <i>Bordetella pertussis</i> in Mice. <i>Infection and Immunity</i> , 2021, 89, .	1.0	16
107	The Path to New Pediatric Vaccines against Pertussis. <i>Vaccines</i> , 2021, 9, 228.	2.1	9
108	Differences in clinical severity of respiratory viral infections in hospitalized children. <i>Scientific Reports</i> , 2021, 11, 5163.	1.6	7
109	Is there a potential for novel, nasal pertussis vaccines?. <i>Expert Review of Vaccines</i> , 2021, 20, 1-9.	2.0	1
110	Pertussis vaccine effectiveness and duration of protection – A systematic review and meta-analysis. <i>Vaccine</i> , 2021, 39, 3120-3130.	1.7	15
111	How Asymptomatic Transmission Influences Mitigation and Suppression Strategies during a Pandemic. <i>Risk Analysis</i> , 2023, 43, 649-659.	1.5	5
112	Infant rhesus macaques as a non-human primate model of <i>Bordetella pertussis</i> infection. <i>BMC Infectious Diseases</i> , 2021, 21, 407.	1.3	7
113	IL-17 mediates protective immunity against nasal infection with <i>Bordetella pertussis</i> by mobilizing neutrophils, especially Siglec-F+ neutrophils. <i>Mucosal Immunology</i> , 2021, 14, 1183-1202.	2.7	39

#	ARTICLE	IF	CITATIONS
115	Asymptomatic <i>Bordetella pertussis</i> infections in a longitudinal cohort of young African infants and their mothers. <i>ELife</i> , 2021, 10, .	2.8	20
116	Cost-Effectiveness of Pertussis Vaccination Schedule in Israel. <i>Vaccines</i> , 2021, 9, 590.	2.1	1
117	Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives. <i>Frontiers in Immunology</i> , 2021, 12, 701285.	2.2	17
118	Long-lived immunity to genetically detoxified pertussis vaccines. <i>EClinicalMedicine</i> , 2021, 37, 101014.	3.2	0
119	<i>Bordetella</i> Adenylate Cyclase Toxin Elicits Airway Mucin Secretion through Activation of the cAMP Response Element Binding Protein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9064.	1.8	3
120	Vaccine-Induced Cellular Immunity against <i>Bordetella pertussis</i> : Harnessing Lessons from Animal and Human Studies to Improve Design and Testing of Novel Pertussis Vaccines. <i>Vaccines</i> , 2021, 9, 877.	2.1	8
121	Lessons from a mature acellular pertussis vaccination program and strategies to overcome suboptimal vaccine effectiveness. <i>Expert Review of Vaccines</i> , 2022, 21, 899-907.	2.0	0
122	PTX Instructs the Development of Lung-Resident Memory T Cells in <i>Bordetella pertussis</i> Infected Mice. <i>Toxins</i> , 2021, 13, 632.	1.5	0
123	The History of Pertussis Toxin. <i>Toxins</i> , 2021, 13, 623.	1.5	14
124	Mucosal Immunization with DTaP Confers Protection against <i>Bordetella pertussis</i> Infection and Cough in Sprague-Dawley Rats. <i>Infection and Immunity</i> , 2021, 89, e0034621.	1.0	7
125	Circulation of <i>Bordetella pertussis</i> in the Caribbean Netherlands: a population-based seroepidemiological study. <i>International Journal of Infectious Diseases</i> , 2021, 111, 21-27.	1.5	0
126	Pathogenicity and virulence of <i>Bordetella pertussis</i> and its adaptation to its strictly human host. <i>Virulence</i> , 2021, 12, 2608-2632.	1.8	26
131	Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans. <i>Journal of Clinical Investigation</i> , 2020, 130, 2332-2346.	3.9	37
132	The relationship between mucosal immunity, nasopharyngeal carriage, asymptomatic transmission and the resurgence of <i>Bordetella pertussis</i> . <i>F1000Research</i> , 2017, 6, 1568.	0.8	28
133	Superspreading events in the transmission dynamics of SARS-CoV-2: Opportunities for interventions and control. <i>PLoS Biology</i> , 2020, 18, e3000897.	2.6	183
134	Is Pertussis Infection Neglected in China? Evidence from a Seroepidemiology Survey in Zhejiang, an Eastern Province of China. <i>PLoS ONE</i> , 2016, 11, e0155965.	1.1	23
135	Knowledge, Attitude and Practice Regarding Pertussis among a Public University Students in Malaysia. <i>Pesquisa Brasileira Em Odontopediatria E Clinica Integrada</i> , 0, 20, .	0.7	1
136	Systematic review and meta-analysis of pertussis epidemiology in Latin America and the Caribbean: 1980-2015. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2017, 41, e102.	0.6	4

#	ARTICLE	IF	CITATIONS
137	Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 265-273.	4.6	12
139	AGENT BASED MODELING: FINE-SCALE SPATIO-TEMPORAL ANALYSIS OF PERTUSSIS. <i>ISPRS Annals of the Photogrammetry, Remote Sensing and Spatial Information Sciences</i> , 0, IV-4/W2, 37-46.	0.0	0
140	The Experience of the Retrospective Epidemiological Analysis of Outbreaks of Pertussis in the Moscow Suburbs. <i>Epidemiologiya I Vaktsinoprofilaktika</i> , 2017, 16, 62-68.	0.2	0
141	Đ—Đ°Ñ...Đ²Đ³⁄₄Ñ€ÑŽĐ²Đ°Đ¹⁄₂Ñ—ÑÑ,ÑŒ Đ¹⁄₂Đ° Đ°Đ°ÑˆĐ»ÑŽĐ° Ñf Đ,ÑŒŒĐ²Ñ—Đ²ÑÑŒŒŒĐ°Ñ—Đ¹ Đ³⁄₄Đ±Đ»Đ°ÑÑ,Ñ-Œ. <i>AktualÉtmaĀc Infek</i>		
143	Analysis of an epidemic model for transmitted diseases in a group of adults and an extension to two age classes. , 2020, 49, 921-934.	0.3	6
144	Evaluation of Outer Membrane Vesicles Obtained from Predominant Local Isolate of <i>Bordetella pertussis</i> as a Vaccine Candidate. <i>Iranian Biomedical Journal</i> , 2021, 25, 399-407.	0.4	1
145	Causes and consequences of delayed vaccination against pertussis infection in the Russian Federation. <i>Zhurnal Mikrobiologii Epidemiologii I Immunobiologii</i> , 2020, 97, 492-502.	0.3	3
146	A Network-Based Compartmental Model For The Spread Of Whooping Cough In Nebraska. <i>AMIA Summits on Translational Science Proceedings</i> , 2019, 2019, 388-397.	0.4	3
147	Epidemiology incidence and geographical distribution of Pertussis using GIS and its incidence prediction in Iran in 2021. <i>Medical Journal of the Islamic Republic of Iran</i> , 2021, 35, 108.	0.9	0
148	Non-primate animal models for pertussis: back to the drawing board?. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 1383.	1.7	0
149	Novel Strategies to Inhibit Pertussis Toxin. <i>Toxins</i> , 2022, 14, 187.	1.5	4
150	The Fim and FhaB adhesins play a crucial role in nasal cavity infection and <i>Bordetella pertussis</i> transmission in a novel mouse catarrhal infection model. <i>PLoS Pathogens</i> , 2022, 18, e1010402.	2.1	9
151	Intranasal Immunization With a c-di-GMP-Adjuvanted Acellular Pertussis Vaccine Provides Superior Immunity Against <i>Bordetella pertussis</i> in a Mouse Model. <i>Frontiers in Immunology</i> , 2022, 13, 878832.	2.2	7
152	Dissecting recurrent waves of pertussis across the boroughs of London. <i>PLoS Computational Biology</i> , 2022, 18, e1009898.	1.5	3
154	Pertussis toxin suppresses dendritic cell-mediated delivery of <i>B. pertussis</i> into lung-draining lymph nodes. <i>PLoS Pathogens</i> , 2022, 18, e1010577.	2.1	5
155	Whole-Cell and Acellular Pertussis Vaccine: Reflections on Efficacy. <i>Medical Principles and Practice</i> , 2022, 31, 313-321.	1.1	5
156	Seroepidemiology of pertussis and diphtheria among healthy adults in Shaanxi Province, northwest China: A large - scale cross-sectional study. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	2
157	Novel approaches to reactivate pertussis immunity. <i>Expert Review of Vaccines</i> , 2022, 21, 1787-1797.	2.0	3

#	ARTICLE	IF	CITATIONS
158	The Catalytic Model. Use R!, 2023, , 87-103.	0.3	0
159	Stochastics. Use R!, 2023, , 165-184.	0.3	0
160	Prior exposure to B. pertussis shapes the mucosal antibody response to acellular pertussis booster vaccination. Nature Communications, 2022, 13, .	5.8	6
161	Evaluation of Whole-Cell and Acellular Pertussis Vaccines in the Context of Long-Term Herd Immunity. Vaccines, 2023, 11, 1.	2.1	3
162	Antigen Discovery for Next-Generation Pertussis Vaccines Using Immunoproteomics and Transposon-Directed Insertion Sequencing. Journal of Infectious Diseases, 2023, 227, 583-591.	1.9	4
163	Genome Sequences of Bordetella pertussis Isolates from Outbreaks in Northeastern Mexico. Microbiology Resource Announcements, 0, , .	0.3	0
164	Incidence and Transmission Dynamics of <i>Bordetella pertussis</i> Infection in Rural and Urban Communities, South Africa, 2016â€™2018. Emerging Infectious Diseases, 2023, 29, 294-303.	2.0	2
165	Evaluation of the effectiveness of maternal immunization against pertussis in Alberta using agent-based modeling: A Canadian immunization research network study. Vaccine, 2023, 41, 2430-2438.	1.7	0
166	Architecture and matrix assembly determinants of Bordetella pertussis biofilms on primary human airway epithelium. PLoS Pathogens, 2023, 19, e1011193.	2.1	2
167	Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanusâ€™diphtheriaâ€™acellular pertussis vaccine: a randomised, double-blind, phase 2b trial. Lancet, The, 2023, 401, 843-855.	6.3	7
168	The incidence, duration, risk factors, and age-based variation of missed opportunities to diagnose pertussis: A population-based cohort study. Infection Control and Hospital Epidemiology, 2023, 44, 1629-1636.	1.0	0
169	A pangenome approach-based loop-mediated isothermal amplification assay for the specific and early detection of Bordetella pertussis. Scientific Reports, 2023, 13, .	1.6	0
170	Maternal vaccination against pertussis as part of the national immunization program: a qualitative evaluation among obstetric care providers one year after the implementation in December 2019. BMC Health Services Research, 2023, 23, .	0.9	0